|
Company Name:
|
Nyrada Inc (ARBN 625 401 818)
|
|
Business Description:
|
Nyrada is a drug development company specialising in novel small molecule therapeutics. A current key focus is on the development of neuroprotective treatments for stroke and traumatic brain injury.
|
|
Established:
|
Nyrada Inc was incorporated in the US State of Delaware on 29 August 2017. It was admitted to the Official List of the Australian Securities Exchange on 14 January 2020.
|
|
Listing:
|
Australian Securities Exchange (ASX:NYR)
|
|
ASX Ticker:
|
NYR
|
|
GICS Industry Group:
|
Pharmaceuticals, Biotechnology & Life Sciences
|
|
Securities on Issue:
|
179,408,700 as at 1 June 2024
|
|
Board of Directors:
|
Mr. John Moore (Non-Executive Chair)
Mr. Christopher Cox (Non-Executive Director)
Dr. Rüdiger Weseloh (Non-Executive Director)
Mr. Marcus Frampton (Non-Executive Director)
Dr. Ian Dixon (Non-Executive Director)
Dr. Gisela Mautner (Non-Executive Director)
|
|
Scientific Advisory Board:
|
Professor Gary Housley (Chair)
Professor Junichi Nabekura (Member)
Dr. Jim Palmer (Member)
|
|
Chief Executive Officer:
|
Mr. James Bonnar
|
|
Chief Financial Officer:
|
Mr Cameron Jones
|
|
Company Secretary:
|
Mr David Franks
|
|
Registered Office:
|
Suite 2, Level 3
828 Pacific Highway
Gordon NSW 2072
Australia
|
|
Company Telephone:
|
+61 2 9498 3390 (Within Australia or Overseas)
|
|
Company Email:
|
info@nyrada.com
|
|
Company Website:
|
www.nyrada.com
|
|
Stock/CDI Registry:
|
Automic Registry Services
Level 5, 126 Phillip Street
Sydney NSW 2000
Australia
|
|
Registry Website:
|
www.automicgroup.com.au
|
|
Registry Telephone:
|
1300 288 664 (Within Australia)
+61 2 9698 5414 (Overseas)
|
|
External Auditor:
|
William Buck
|
